Jochen Heymanns - Concepedia

Author

Jochen Heymanns

Also Known As

Cordula Schardt, Heymanns, Jochen, J HEYMANNS, J Heymanns, J. HEYMANNS, J. Heymanns, J. Heymanns, Jochen Heymanns, M. Kneba

105

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Philipps University of Marburg Praxis für Hämatologie und Onkologie Institut für Versorgungsforschung in der Onkologie Koblenz University of Applied Sciences Johannes Gutenberg University Mainz

About

Jochen Heymanns is an author at Philipps University of Marburg specializing in medicine, cancer research, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	298
2	Allergy	2	2	34
3	Education	1	1	10
4	Health Sciences	1	1	11
5	Social Sciences	1	1	21

Jochen Heymanns

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV Susanne Saußele, Marie-Paloma Krauß, Rüdiger Hehlmann, Blood	2015	197
Persistent Long-Term Changes In Lymphocyte Subsets Induced By Polyclonal Antibodies1 Thomas F. M ller, Scott O. Grebe, Maria Neumann, Transplantation	1997	138
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG) Rudolf Weide, H. Köppler, Jochen Heymanns, Leukemia & lymphoma/Leukemia and lymphoma	2007	97
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy Rudolf Weide, Jochen Heymanns, Annette Pandorf, Lupus	2003	87
Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects Gerold Bepler, Martin Rotsch, Gabriele Jaques, Journal of Cancer Research and Clinical Oncology Cancer ResearchPeptide LibraryPeptide TherapeuticBronchial NeoplasmGrowth Factors	1988	75
Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study Rudolf Weide, Annette Pandorf, Jochen Heymanns, Leukemia & lymphoma/Leukemia and lymphoma	2004	66
Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function H. Lange, Thomas F. Müller, H. Ebel, Transplant International	1999	43
SUCCESSFUL TREATMENT OF CLOZAPINE INDUCED AGRANULOCYTOSIS WITH GRANULOCYTE‐COLONY STIMULATING FACTOR (G‐CSF) Rudolf Weide, H. Köppler, Jochen Heymanns, British Journal of Haematology PharmacologyMedicine	1992	42
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors Rudolf Weide, Stefan Feiten, Vera Friesenhahn, SpringerPlus	2014	42
The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti‐CD20 monoclonal antibody rituximab Rudolf Weide, Jochen Heymanns, H. Köppler British Journal of Haematology	2000	40

Page 1